Treatment-Free Remission—A New Aim in the Treatment of Chronic Myeloid Leukemia

Treatment-Free Remission—A New Aim in the Treatment of Chronic Myeloid Leukemia

Tyrosine kinases inhibitors (TKIs) revolutionized chronic myeloid leukemia (CML) treatment for many years, prolonging patients’ life expectancy to be comparable to age-matched healthy individuals. According to the latest the European LeukemiaNet (ELN) recommendations, CML treatment aims to achieve l...

Full description

Bibliographic Details
Main Authors:	Paulina Kwaśnik, Krzysztof Giannopoulos
Format:	Article
Language:	English
Published:	MDPI AG 2021-07-01
Series:	Journal of Personalized Medicine
Subjects:	chronic myeloid leukemia (CML) tyrosine kinases inhibitors (TKIs) treatment-free remission (TFR) TKI withdrawal syndrome
Online Access:	https://www.mdpi.com/2075-4426/11/8/697

Similar Items

Modelling of immune response in chronic myeloid leukemia patients suggests potential for treatment reduction prior to cessation
by: Elena Karg, et al.
Published: (2022-12-01)

WHO 2016 Definition of Chronic Myeloid Leukemia and Tyrosine Kinase Inhibitors
by: İbrahim C. Haznedaroğlu, et al.
Published: (2020-02-01)

Treatment free remission in chronic myeloid leukemia: Lights and shadows
by: Matteo Molica, et al.
Published: (2020-09-01)

Treatment-Free Remission in Chronic Myeloid Leukemia: Can We Identify Prognostic Factors?
by: Hilbeen Hisham Saifullah, et al.
Published: (2021-08-01)

Digital PCR as a New Method for Minimal Residual Disease Monitoring and Treatment Free Remission Management in Chronic Myeloid Leukemia Patients: Is It Reliable?
by: Simona Bernardi, et al.
Published: (2022-12-01)

Monitoring the response to tyrosine kinase inhibitor (TKI) treatment in chronic myeloid leukemia (CML)
by: Ibrahim C. Haznedaroglu
Published: (2014-08-01)

Tyrosine Kinase Inhibitors in pediatric chronic myeloid leukemia: a focused review of clinical trials
by: Fateen Ata, et al.
Published: (2023-12-01)

Chronic Myeloid Leukemia, from Pathophysiology to Treatment-Free Remission: A Narrative Literature Review
by: Rinaldi I, et al.
Published: (2023-04-01)

Bullous Pemphigoid Occurring after Stopping Imatinib Therapy of CML: Is a Continuation of Post-Treatment Follow-Up Needed?
by: Alexander Yakobson, et al.
Published: (2023-09-01)

Treatment-Free Remission in Chronic Myeloid Leukemia and New Approaches by Targeting Leukemia Stem Cells
by: Yilin Chen, et al.
Published: (2021-10-01)

CD26/DPP-4 in Chronic Myeloid Leukemia
by: Anna Sicuranza, et al.
Published: (2022-02-01)

Chronic myeloid leukemia patients and treatment-free remission attitudes: a multicenter survey
by: Lou J, et al.
Published: (2018-06-01)

Treatment-free remission in patients with chronic myeloid leukemia: literature review
by: A. N. Petrova, et al.
Published: (2019-10-01)

Clinical and Psychological Factors to Consider in Achieving Treatment-Free Remission in Patients With Chronic Myeloid Leukemia
by: Massimo Breccia, et al.
Published: (2021-03-01)

Accelerated Phase Chronic Myeloid Leukemia and Treatment Free Remission Maintained After Five Years of Nilotinib: A Case Report
by: Isabella Capodanno, et al.
Published: (2021-06-01)

Spontaneous Remission in a Patient with Chronic Myeloid Leukemia: A Case Report
by: Awni Alshurafa, et al.
Published: (2023-10-01)

Evaluation of tyrosine kinase inhibitor discontinuation initiative in patients with chronic myeloid leukemia at princess noorah oncology center
by: Afnan Mohammed Noor, et al.
Published: (2022-01-01)

Presence of Myeloid Mutations in Patients with Chronic Myeloid Leukemia Increases Risk of Cardiovascular Event on Tyrosine Kinase Inhibitor Treatment
by: Ruth Stuckey, et al.
Published: (2023-06-01)

Current Strategies and Future Directions to Achieve Deep Molecular Response and Treatment-Free Remission in Chronic Myeloid Leukemia
by: Mario Annunziata, et al.
Published: (2020-06-01)

Multidisciplinary management in chronic myeloid leukemia improves cardiovascular risk measured by SCORE
by: Alberto Blanco Sánchez, et al.
Published: (2023-07-01)

Debating Frontline Therapy in Chronic Myeloid Leukemia
by: Xia Bi, et al.
Published: (2021-09-01)

Chronic Myeloid Leukemia in Children: Immune Function and Vaccinations
by: Meinolf Suttorp, et al.
Published: (2021-09-01)

Treatment free remission in pediatric chronic myeloid leukemia
by: Meena Satishkumar, et al.
Published: (2023-03-01)

Are Successful Pregnancies an Achievable Goal in Patients with Chronic Myeloid Leukaemia?
by: Zhanet Grudeva-Popova, et al.
Published: (2019-08-01)

De‐escalation or discontinuation of tyrosine kinase inhibitor in patients with chronic myeloid leukemia: A multicentral, open‐label, prospective trial in China
by: Jie Luo, et al.
Published: (2022-11-01)

Targeting integrated stress response with ISRIB combined with imatinib treatment attenuates RAS/RAF/MAPK and STAT5 signaling and eradicates chronic myeloid leukemia cells
by: Wioleta Dudka, et al.
Published: (2022-12-01)

Budget Impact analysis of the first-line treatment of Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) adult patients
by: Francesco Mennini, et al.
Published: (2017-07-01)

An observational study on risk of secondary cancers in chronic myeloid leukemia patients in the TKI era in the United States
by: Vivek Kumar, et al.
Published: (2018-02-01)

Outcomes of Chronic Phase Chronic Myeloid Leukemia after Treatment with Multiple Tyrosine Kinase Inhibitors
by: Jee Hyun Kong, et al.
Published: (2020-05-01)

A clinician perspective on the treatment of chronic myeloid leukemia in the chronic phase
by: Valentin García-Gutiérrez, et al.
Published: (2022-07-01)

Vaccination With Live Attenuated Vaccines in Four Children With Chronic Myeloid Leukemia While on Imatinib Treatment
by: Claudia Bettoni da Cunha-Riehm, et al.
Published: (2020-04-01)

Digital PCR improves the quantitation of DMR and the selection of CML candidates to TKIs discontinuation
by: Simona Bernardi, et al.
Published: (2019-05-01)

A Multicenter Retrospective Chart Review Study of Treatment and Disease Patterns and Clinical Outcomes of Patients with Chronic-Phase Chronic Myeloid Leukemia in Third-Line Treatment or with T315I Mutation
by: Franck-Emmanuel Nicolini, et al.
Published: (2023-08-01)

Management of chronic myeloid leukaemia: current treatment options, challenges, and future strategies
by: Salma Younes, et al.
Published: (2023-12-01)

Incidences of Deep Molecular Responses and Treatment-Free Remission in de Novo CP-CML Patients
by: Gabriel Etienne, et al.
Published: (2020-09-01)

Identification of Immunological Parameters as Predictive Biomarkers of Relapse in Patients with Chronic Myeloid Leukemia on Treatment-Free Remission
by: Lorena Vigón, et al.
Published: (2020-12-01)

Regulatory T Cell as a Biomarker of Treatment-Free Remission in Patients with Chronic Myeloid Leukemia
by: Yuki Fujioka, et al.
Published: (2021-11-01)

Telomere length shortening is associated with treatment-free remission in chronic myeloid leukemia patients
by: Giovanni Caocci, et al.
Published: (2016-07-01)

The Importance of Mutational Analysis in Chronic Myeloid Leukaemia for Treatment Choice
by: Hugues de Lavallade, et al.
Published: (2016-11-01)

Targeted Next-Generation Sequencing Identifies Additional Mutations Other than <i>BCR∷ABL</i> in Chronic Myeloid Leukemia Patients: A Chinese Monocentric Retrospective Study
by: Shiwei Hu, et al.
Published: (2022-11-01)